Try our beta test site

Partnership for Glaucoma

This study has been completed.
University of Alabama at Birmingham
Information provided by (Responsible Party):
Duke University Identifier:
First received: May 4, 2008
Last updated: January 3, 2014
Last verified: December 2013
The purpose of this study is to develop new ways of assisting patients with glaucoma and their eye doctors in using the recommendations from practice guidelines.

Condition Intervention
Other: Computer Tablet
Other: Continuing Education Course
Other: Continuing education

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Expanding Quality Care for Glaucoma Through a Provider-Patient Partnership

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • To determine if innovative technology will improve process quality of care & important outcomes of care by optometrists in a cost-efficient manner while simultaneously empowering & including patients as part of the care process. [ Time Frame: Baseline, Year 1 and Year 2 ]

Enrollment: 721
Study Start Date: October 2007
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Other: Computer Tablet
A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
Other: Continuing Education Course
Annual standard continuing education
Control group to receive annual continuing education
Other: Continuing education
Annual standard continuing education materials

Detailed Description:

Glaucoma is a leading cause of blindness and visual impairment in the United States, particularly among disadvantaged populations. Despite the presence of therapies proven in NEI, randomized controlled trials that can be delivered by more than 18,000 ophthalmologists and 34,000 optometrists, almost nothing is known about the content and quality of glaucoma care delivered by non-MD providers such as optometrists. With the numbers of people with glaucoma expected to more than double in the next twenty years in the face of no more than a 15% increase in the supply of eye care providers, methods to better support appropriate and high-quality care for chronic eye diseases such as glaucoma delivered by optometrists will become as critical, if not more so, as techniques to enhance quality care among ophthalmologists.

Our study is a community-based, randomized, controlled trial that evaluates the suitability and effectiveness of a technology-based (tablet computer) intervention within the context of a novel partnership between optometrists and patients with glaucoma to improve the process quality of care and ultimately outcomes of care. By using successfully implemented technology in novel applications,and by building on the success of ongoing community-based quality improvement projects in our region, the study provides a means for rapid translation into community care if the intervention is successful.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

-Diagnosis of open angle glaucoma with documented visual field loss.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00672048

United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35204
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
University of Alabama at Birmingham
Principal Investigator: Paul Lee, MD, JD Duke University